MétaCan
Menu
Back to cohort

Impact of duration of adjuvant therapy (AT) on cancer survival.

2014· article· en· W2906729146 on OpenAlexaff
Aalok Kumar, Renata D’Alpino Peixoto, Sharlene Gill, Hagen F. Kennecke, Daniel J. Renouf, Howard J. Lim, Caroline Speers, Winson Y. Cheung

Bibliographic record

VenueJournal of Clinical Oncology · 2014
Typearticle
Languageen
FieldMedicine
TopicColorectal Cancer Treatments and Studies
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsMedicineFOLFOXInternal medicineProportional hazards modelDiscontinuationCancerCohortPopulationStage (stratigraphy)Logistic regressionHazard ratioSurgeryOncologyColorectal cancerConfidence intervalOxaliplatin

Abstract

fetched live from OpenAlex

6513 Background: Trials demonstrate that patients (pts) with specific cancers who complete AT experience better outcomes than those who do not. However, the magnitude of benefit in pts who discontinue AT early is poorly defined. Using a population-based cohort of stage III colon cancer (CC) pts, our aims were to (1) examine the rate of receiving all planned AT, (2) determine the factors associated with AT completion, and (3) explore the relationship between early AT discontinuation and survival. Methods: We analyzed pts diagnosed with stage III CC from 2006 to 2010 and initiated at least 1 cycle of adjuvant FOLFOX at any 1 of 5 regional cancer centers in British Columbia. Logistic regression models were constructed to determine the factors associated with AT completion, which was defined as receipt of >/= 10 cycles of FOLFOX. Kaplan-Meier methods and Cox regression that accounted for prognostic factors were used to evaluate the relationship between early AT discontinuation and disease-free (DFS) and overall survival (OS). Results: We identified 616 patients: median age 62 years (range 26-80), 52% men, 87% T3/4 tumors, and 40% N2 disease. Among them, 183 (30%) received < 10 and 433 (70%) underwent >/= 10 cycles. Adjusting for confounders, men and those with obstruction/perforation were more likely to discontinue AT early (OR for AT completion 0.62, 95%CI 0.43-0.89, p=0.01 and 0.55, 95%CI 0.33-0.92, p=0.02, respectively). In terms of survival, T3/4 stage, N2 disease and long post-operative recovery of >/= 1 week were correlated with worse DFS, while T4 stage and N2 disease were also associated with inferior OS. However, early discontinuation of AT did not impact DFS and OS (Table). Sensitivity analyses using different definitions for AT completion produced similar findings. Conclusions: Early discontinuation of adjuvant FOLFOX was not associated with significant survival differences, lending support to trials that are underway evaluating the utility of shorter durations of AT. DFS OS HR p HR p >/=10 cycles 1.0 .40 1.0 .76 <10 cycles 1.15 1.07 No obstruction/perforation 1.0 <.001 1.0 .13 Obstruction/perforation 1.95 1.47 T1/2 1.0 .02 1.0 .09 T3 2.31 <.001 2.19 .002 T4 3.72 4.44 N1 1.0 <.001 1.0 .002 N2 1.95 1.83 <7 days post-op stay 1.0 .049 1.0 .49 >/=7 days post-op stay 1.47 1.19

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.006
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.218
GPT teacher head0.550
Teacher spread0.333 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicColorectal Cancer Treatments and StudiesFrench-language works237,207